Biomedical drugs could be an alternative to prescription drugs, according to Health Line. It’s important to know that one of the most significant but perhaps less understood breakthroughs in healthcare in recent years has been the availability of biosimilars.
Biosimilars are drugs that are highly similar to the biologic drugs on which biosimilars are based. When a biopharmaceutical company’s patent or exclusivity protection for its biologic drug expires in the United States, biosimilars that have actually received U.S. Food and Drug Administration (FDA) approval can then enter the marketplace and compete with that existing drug.
Medical expery say that biosimilars, which have to go go through a thorough and complicated review by the FDA, provide the very same benefits for patients as the original drug and demonstrate no clinically meaningful difference from the existing biological drug in terms of safety, potency or purity of content.
In an long and thorough review of science literature evaluating patients who switched from regular prescription medicines to biosimilars, Hillel Cohen, executive director of scientific affairs at Sandoz Biopharmaceuticals (a Novartis company), and her fellow researchers looked at 90 biosimilar studies that enrolled 14,225 patients.
Thelie results showed that safety concerns and efficacy were not changed after patients made the switch.
“Biosimilars offer affordable options that increase access with no compromise in safety, efficacy, or quality,” Gillian Woollett, MA, DPhil, a senior vice president at Avalere Health and research scientist in immunology who’s worked for many years in the biotech industry says. These drugs however are not mentioned by doctors and aren’t promoted. That probably should change.